Please turn JavaScript on
Find more feeds
Hospital Management icon

Hospital Management

Want to know the latest news and articles posted on Hospital Management?

Then subscribe to their feed now! You can receive their updates by email, via mobile or on your personal news page on this website.

See what they recently published below.

Website title: Hospital Management - The leading site for news and procurement in the hospital sector

Is this your feed? Claim it!

Publisher:  Unclaimed!
Message frequency:  2.05 / day

Message History

First participant receives Evategrel in CureGene’s trial
CureGene Pharmaceutical has dosed the first participant in its pivotal clinical trial of Evategrel, a next-generation antiplatelet therapy, in the US.

The post First participant receives Evategrel in CureGene’s trial appeared f...


Read full story
Imperative Care reports SYMPHONY-PE trial data for pulmonary embolism
Imperative Care has reported results from a post-hoc analysis of the SYMPHONY-PE Trial, assessing the role of early mechanical thrombectomy in patients diagnosed with intermediate-risk PE.

The post Imperative Care reports SYMPHONY-PE trial data ...


Read full story
Japan approves Sanofi’s Sarclisa combo for MM treatment
Sanofi has received approval from Japan's Ministry of Health, Labour and Welfare for its SC formulation of Sarclisa in combination with standard therapies to treat multiple myeloma.

The post Japan approves Sanofi’s Sarclisa combo for MM treatment<...


Read full story
Charles River collaborates with Lilly TuneLab platform
Charles River Laboratories has entered a collaboration with Eli Lilly and Company’s AI/ML-focused drug discovery platform, Lilly TuneLab.

The post Charles River collaborates with Lilly TuneLab platform appeared first on


Read full story
MAIA activates new site for THIO-101 Phase II trial
MAIA Biotechnology has activated new US site, the Winship Cancer Institute of Emory University, and opened patient enrolment for the Phase II THIO-101 expansion trial evaluating its telomere-targeting agent, ateganosine, as a third-line therapy for NSCLC.

The post


Read full story